Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors
13 juil. 2022 07h00 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236
28 juin 2022 07h00 HE
|
Revolution Medicines, Inc.
First-in-class, oral, RAS(ON) Inhibitor being evaluated initially in patients with cancers driven by KRASG12 mutations Sushil Patel, Ph.D., industry veteran with commercial oncology expertise,...
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2021 After Market Close on February 28, 2022
22 févr. 2022 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference
03 févr. 2022 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference
04 janv. 2022 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted...
Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference
08 nov. 2021 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit
15 sept. 2021 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference
07 sept. 2021 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress
11 août 2021 16h01 HE
|
Revolution Medicines, Inc.
Company Shows Continued Progress Demonstrating Differentiation of RAS(ON) Inhibitors, Targeting Additional RAS Variants and Progressing Assets Toward the Clinic Initial Results of RMC-4630-02 Study...
Revolution Medicines to Report Financial Results for Second Quarter 2021 After Market Close on August 11, 2021
04 août 2021 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...